VIDEO: Skyrizi induces clinical remission, endoscopic response in Crohn’s
Click Here to Manage Email Alerts
In a video exclusive, Remo Panaccione, MD, University of Calgary, discusses his research showing Skyrizi bested placebo in inducing clinical remission in patients with Crohn’s disease.
These results follow patients with moderate to severe CD who failed prior biologic treatment from the phase 3 MOTIVATE study. Patients received 600 mg or 1200 mg, of Skyrizi (risankizumab, AbbVie) or placebo at weeks 0, 4 and 8 and those that received the treatment drug showed greater rates of remission.
“The exciting news for our field is that when you look at patients who had failed one biologic therapy, which may have been multiple mechanisms of action, that risankizumab performed just as well as it did in the entire population,” Panaccione said. “Even in patients who had failed more than one biologic, it still performed better than placebo and was statistically significant.”
Collapse
Panaccione R, et al. Abstract OP194. Presented at: UEG Week; Oct. 3-5, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts